X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs SUN PHARMA - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA SUN PHARMA DISHMAN PHARMA/
SUN PHARMA
 
P/E (TTM) x 25.1 26.4 95.1% View Chart
P/BV x 3.3 3.9 86.8% View Chart
Dividend Yield % 0.7 0.6 111.4%  

Financials

 DISHMAN PHARMA   SUN PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
SUN PHARMA
Mar-17
DISHMAN PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs374842 44.5%   
Low Rs129572 22.5%   
Sales per share (Unadj.) Rs197.8131.6 150.3%  
Earnings per share (Unadj.) Rs21.232.7 64.8%  
Cash flow per share (Unadj.) Rs34.738.0 91.4%  
Dividends per share (Unadj.) Rs2.003.50 57.1%  
Dividend yield (eoy) %0.80.5 160.6%  
Book value per share (Unadj.) Rs179.9152.7 117.8%  
Shares outstanding (eoy) m80.692,399.26 3.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.35.4 23.7%   
Avg P/E ratio x11.921.6 54.9%  
P/CF ratio (eoy) x7.218.6 38.9%  
Price / Book Value ratio x1.44.6 30.2%  
Dividend payout %9.410.7 88.1%   
Avg Mkt Cap Rs m20,3061,696,877 1.2%   
No. of employees `0000.817.5 4.7%   
Total wages/salary Rs m5,35549,023 10.9%   
Avg. sales/employee Rs Th19,252.718,028.3 106.8%   
Avg. wages/employee Rs Th6,459.52,798.8 230.8%   
Avg. net profit/employee Rs Th2,064.14,479.5 46.1%   
INCOME DATA
Net Sales Rs m15,961315,784 5.1%  
Other income Rs m2656,232 4.3%   
Total revenues Rs m16,226322,016 5.0%   
Gross profit Rs m4,103100,893 4.1%  
Depreciation Rs m1,09112,648 8.6%   
Interest Rs m9443,998 23.6%   
Profit before tax Rs m2,33490,479 2.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m199 1.1%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m62412,116 5.1%   
Profit after tax Rs m1,71178,462 2.2%  
Gross profit margin %25.731.9 80.5%  
Effective tax rate %26.713.4 199.6%   
Net profit margin %10.724.8 43.1%  
BALANCE SHEET DATA
Current assets Rs m11,018329,537 3.3%   
Current liabilities Rs m9,517178,870 5.3%   
Net working cap to sales %9.447.7 19.7%  
Current ratio x1.21.8 62.8%  
Inventory Days Days11079 139.9%  
Debtors Days Days3583 41.8%  
Net fixed assets Rs m16,304204,766 8.0%   
Share capital Rs m1612,399 6.7%   
"Free" reserves Rs m12,907363,997 3.5%   
Net worth Rs m14,516366,397 4.0%   
Long term debt Rs m4,18914,361 29.2%   
Total assets Rs m29,805614,102 4.9%  
Interest coverage x3.523.6 14.7%   
Debt to equity ratio x0.30 736.4%  
Sales to assets ratio x0.50.5 104.1%   
Return on assets %8.913.4 66.4%  
Return on equity %11.821.4 55.0%  
Return on capital %17.524.8 70.6%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95244,118 11.2%   
Fx outflow Rs m69724,484 2.8%   
Net fx Rs m4,25519,634 21.7%   
CASH FLOW
From Operations Rs m2,78670,822 3.9%  
From Investments Rs m-1,529-42,216 3.6%  
From Financial Activity Rs m-941-22,854 4.1%  
Net Cashflow Rs m3166,107 5.2%  

Share Holding

Indian Promoters % 61.4 63.7 96.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 5.1 72.1%  
FIIs % 12.7 23.0 55.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 8.3 266.3%  
Shareholders   46,261 133,026 34.8%  
Pledged promoter(s) holding % 35.8 0.5 6,747.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   ALKEM LABORATORIES  FRESENIUS KABI ONCO.  FDC LTD.  ASTRAZENECA PHARMA  BIOCON LTD  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Idea Plunges 5% on Weak Q3 Peformance(Closing)

Indian share markets finished on a flat note after a five-session record-setting spree as profit booking was witnessed in metal stocks, capital goods stocks.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

'Smart Money' Enters Bitcoin. Will You?(Smart Contrarian)

Jan 17, 2018

As institutional money enters bitcoin, the gains over the last year could just be the tip of the iceberg.

Increasing Divergence Between Bond Yields and Earnings Yield(Chart Of The Day)

Jan 11, 2018

Over the past couple of months, bond yields have risen, but earning yields have fallen, increasing divergence.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS